Almatica announces third SNRI/SSRI branded CNS product launch this year, offering yet another simplified dose option delivered to market for patients with MDD and anxiety disorders.
Venlafaxine Extended-Release Tablets 112.5 mg is indicated for the Treatment of Major Depressive Disorder and Generalized Anxiety Disorder in Adults: link: https://www.venlafaxine112-5.com/